47-Target Safety Panel Screening Services

Early identification of off-target activity is one of the most cost-effective ways to de-risk a drug discovery program. ICE Bioscience's 47-target safety panel screening service profiles compounds against a curated set of safety-relevant targets, helping project teams flag potential liabilities before committing to costly in vivo studies.

Panel Coverage

The 47-target safety panel covers GPCRs, ion channels, enzymes, transporters and nuclear receptors that are commonly associated with adverse drug reactions. Compounds are typically tested in dose-response format, generating IC50 data that allows direct comparison of off-target potency against primary target activity.

What You Receive

• Standardized, validated assay conditions across all 47 targets
• Clear IC50 and percent-inhibition data for each target
• Structured reports suitable for internal review and candidate selection meetings
• Optional follow-up studies for confirmed hits

Part of a Complete Safety Strategy

The 47-target safety panel complements ICE Bioscience's broader in vitro safety pharmacology offering, including hERG testing, ion channel selectivity panels and ICESTP safety panels, enabling a staged, efficient approach to early safety assessment.

If you would like to learn more about this service or discuss your project, please contact our team for a tailored proposal and quotation.